Jane R. Schwebke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jane R. Schwebke has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Christina A. Muzny
Division of Infectious Diseases, University of Alabama at Birmingham , Birmingham, Alabama
5 shared publications Renee A. Desmond
5 shared publicationsRenee Desmond
3 shared publicationsC. A. Rivers
University of Alabama at Birmingham, Department of Medicine, Birmingham, Alabama, USA
2 shared publicationsJ. Y. Lee
University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
2 shared publications- Jeannette Y. Lee
University of Arkansas for Medical Sciences, Little Rock, AR
2 shared publications
Latest Publications
- 30 November 2020
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 47 (12) , E58-E61
Use of a Novel Couples' Verification Tool in a Male Partner Treatment Study of Women With Recurrent Bacterial Vaginosis
Verification of relationship status beyond self-report is an important aspect in sexually transmitted infection research, including partner treatment studies where primary sexual partners are targeted for enrollment. This exploratory study describes the use of a novel couples' verification tool in a male partner treatment study of women with recurrent bacterial vaginosis.
- 30 November 2020
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 47 (12) , E58-E61
Use of a Novel Couples' Verification Tool in a Male Partner Treatment Study of Women With Recurrent Bacterial Vaginosis
Verification of relationship status beyond self-report is an important aspect in sexually transmitted infection research, including partner treatment studies where primary sexual partners are targeted for enrollment. This exploratory study describes the use of a novel couples' verification tool in a male partner treatment study of women with recurrent bacterial vaginosis.
- 1 December 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 217 (6) , 678.e1-678.e9
A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis
- 1 December 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 217 (6) , 678.e1-678.e9
A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis
- 19 July 2016
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 214 (suppl 1) , S1-S5
Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses
In April 2015, the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases hosted an experts technical consultation on bacterial vaginosis (BV), where data regarding controversies over the pathogenesis of BV were discussed. The discussion on the epidemiology and pathogenesis of BV is presented here, and several hypotheses on its pathogenesis are critiqued. Rigorous hypothesis-driven studies are needed to ultimately determine the cause of BV. This information is vital for the prevention and control of this important infection and its adverse public health consequences.
- 19 July 2016
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 214 (suppl 1) , S1-S5
Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses
In April 2015, the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases hosted an experts technical consultation on bacterial vaginosis (BV), where data regarding controversies over the pathogenesis of BV were discussed. The discussion on the epidemiology and pathogenesis of BV is presented here, and several hypotheses on its pathogenesis are critiqued. Rigorous hypothesis-driven studies are needed to ultimately determine the cause of BV. This information is vital for the prevention and control of this important infection and its adverse public health consequences.
- Open Access
- 26 November 2015
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 62 (5) , 531-536
Home Screening for Bacterial Vaginosis to Prevent Sexually Transmitted Diseases
Background. Longitudinal studies have consistently found a significant association between bacterial vaginosis (BV) and acquisition of sexually transmitted diseases. However, there are limited prospective data to confirm these findings. Methods. We conducted a prospective, randomized, open-label trial of home screening and treatment of young women with asymptomatic BV who were also at high risk for sexually transmitted diseases. These women were screened every 2 months for 12 months and randomized to treatment with oral metronidazole 500 mg twice daily for 7 days or observation alone. The primary outcome was the incidence of gonorrhea and/or chlamydia. Results. A total of 1365 subjects were enrolled in the study across 10 sites. Adherence with mailing specimens obtained at home was excellent in both groups (84%–88%). The incidence of gonorrhea and/or chlamydia was 19.1 per 100 person-years (95% confidence interval, 15.1–22.1) for the treatment group and 18.5 per 100 person-years (15.1–22.8) for the observation arm, a difference that was not statistically significant. Conclusions. Young women were very amenable to home screening for BV, gonorrhea, and chlamydia. Treatment of asymptomatic BV with 1 week of oral metronidazole did not decrease the incidence of gonorrhea and/or chlamydia. Clinical Trials Registration. NCT00667368.
- 26 November 2015
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 62 (5) , 531-536
Open AccessHome Screening for Bacterial Vaginosis to Prevent Sexually Transmitted Diseases
Background. Longitudinal studies have consistently found a significant association between bacterial vaginosis (BV) and acquisition of sexually transmitted diseases. However, there are limited prospective data to confirm these findings. Methods. We conducted a prospective, randomized, open-label trial of home screening and treatment of young women with asymptomatic BV who were also at high risk for sexually transmitted diseases. These women were screened every 2 months for 12 months and randomized to treatment with oral metronidazole 500 mg twice daily for 7 days or observation alone. The primary outcome was the incidence of gonorrhea and/or chlamydia. Results. A total of 1365 subjects were enrolled in the study across 10 sites. Adherence with mailing specimens obtained at home was excellent in both groups (84%–88%). The incidence of gonorrhea and/or chlamydia was 19.1 per 100 person-years (95% confidence interval, 15.1–22.1) for the treatment group and 18.5 per 100 person-years (15.1–22.8) for the observation arm, a difference that was not statistically significant. Conclusions. Young women were very amenable to home screening for BV, gonorrhea, and chlamydia. Treatment of asymptomatic BV with 1 week of oral metronidazole did not decrease the incidence of gonorrhea and/or chlamydia. Clinical Trials Registration. NCT00667368.
- Open Access
- 1 July 2015
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 42 (7) , 376-381
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis
Bacterial vaginosis (BV), a prevalent infection in women of reproductive age, is associated with increased risk of upper genital tract and sexually transmitted infections, and complications in pregnancy. Currently approved treatments include metronidazole, which requires once or twice daily intravaginal administration for 5 days or twice daily oral administration for 7 days. This phase 3 study determined the safety and efficacy of single-dose metronidazole vaginal gel (MVG) 1.3%. In this double-blind, vehicle-controlled study, 651 women with clinical diagnosis of BV were randomized 1:1 to receive MVG 1.3% or vehicle vaginal gel. Primary efficacy measure was clinical cure (normal discharge, negative "whiff test," and <20% clue cells) at day 21. Secondary measures included therapeutic cure (both clinical and bacteriological; day 21) and bacteriologic cure (Nugent score <4), clinical cure, and time to resolution of symptoms (day 7). A total of 487 participants were included in the primary analysis. Clinical and therapeutic cure rates (day 21) were higher in participants treated with MVG 1.3% compared with vehicle gel (37.2% vs. 26.6% [P = 0.010] and 16.8% vs. 7.2% [P = 0.001], respectively). Clinical and bacteriologic cure rates (day 7) were also higher in the MVG 1.3% group (46.0% vs. 20.0% [P < 0.001] and 32.7% vs. 6.3% [P < 0.001], respectively). The median time to resolution of symptoms was shorter in the MVG 1.3% (day 6) than vehicle group (not reached). No serious adverse events were reported, and incidence was similar across treatment groups. Single-dose MVG 1.3% was safe and superior to vehicle gel in producing cure among women with BV.
- 1 July 2015
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 42 (7) , 376-381
Open AccessA Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis
Bacterial vaginosis (BV), a prevalent infection in women of reproductive age, is associated with increased risk of upper genital tract and sexually transmitted infections, and complications in pregnancy. Currently approved treatments include metronidazole, which requires once or twice daily intravaginal administration for 5 days or twice daily oral administration for 7 days. This phase 3 study determined the safety and efficacy of single-dose metronidazole vaginal gel (MVG) 1.3%. In this double-blind, vehicle-controlled study, 651 women with clinical diagnosis of BV were randomized 1:1 to receive MVG 1.3% or vehicle vaginal gel. Primary efficacy measure was clinical cure (normal discharge, negative "whiff test," and <20% clue cells) at day 21. Secondary measures included therapeutic cure (both clinical and bacteriological; day 21) and bacteriologic cure (Nugent score <4), clinical cure, and time to resolution of symptoms (day 7). A total of 487 participants were included in the primary analysis. Clinical and therapeutic cure rates (day 21) were higher in participants treated with MVG 1.3% compared with vehicle gel (37.2% vs. 26.6% [P = 0.010] and 16.8% vs. 7.2% [P = 0.001], respectively). Clinical and bacteriologic cure rates (day 7) were also higher in the MVG 1.3% group (46.0% vs. 20.0% [P < 0.001] and 32.7% vs. 6.3% [P < 0.001], respectively). The median time to resolution of symptoms was shorter in the MVG 1.3% (day 6) than vehicle group (not reached). No serious adverse events were reported, and incidence was similar across treatment groups. Single-dose MVG 1.3% was safe and superior to vehicle gel in producing cure among women with BV.
- Open Access
- 1 July 2015
- Published by American Society for Microbiology in mBio
- Vol. 6 (3) , e00819-15
Accuracy of Self-Report of Sexual Activity among Adolescent Girls: Implications for Interpretation of Vaginal Flora Patterns
- 1 July 2015
- Published by American Society for Microbiology in mBio
- Vol. 6 (3) , e00819-15
Open AccessAccuracy of Self-Report of Sexual Activity among Adolescent Girls: Implications for Interpretation of Vaginal Flora Patterns
- Open Access
- 16 December 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (7) , 1054-1056
Editorial Commentary: Women Who Have Sex With Women: A Unique Population for Studying the Pathogenesis of Bacterial Vaginosis
(See the Major Article by Vodstrcil et al on pages 1042–53.)
- 16 December 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (7) , 1054-1056
Open AccessEditorial Commentary: Women Who Have Sex With Women: A Unique Population for Studying the Pathogenesis of Bacterial Vaginosis
(See the Major Article by Vodstrcil et al on pages 1042–53.)
- Open Access
- 1 May 2014
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 52 (5) , 1698-1700
ESwab as an Optional Collection Device for Use with the Affirm VPIII Microbial Test System
The ESwab collection device was compared to the collection swab provided as part of the Affirm VPIII microbial identification test kit for testing vaginal specimens with the Affirm test system. There was excellent agreement between the two sampling devices for Candida spp., Gardnerella vaginalis , and Trichomonas vaginalis .
- 1 May 2014
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 52 (5) , 1698-1700
Open AccessESwab as an Optional Collection Device for Use with the Affirm VPIII Microbial Test System
The ESwab collection device was compared to the collection swab provided as part of the Affirm VPIII microbial identification test kit for testing vaginal specimens with the Affirm test system. There was excellent agreement between the two sampling devices for Candida spp., Gardnerella vaginalis , and Trichomonas vaginalis .
- Top Cited PapersOpen Access
- 2 December 2013
- Published by Springer Nature in Microbiome
- Vol. 1 (1) , 29
Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis
Bacterial vaginosis (BV) is a common gynecologic diagnosis characterized by dysbiosis of the vaginal microbiota. It is often accompanied by vaginal symptoms such as odor and discharge, but can be asymptomatic. Despite over 50 years of research, the etiology of BV is not well understood, which is a major impediment to treatment and prevention of BV. Here we report on the temporal dynamics of 25 vaginal communities over a 10 week period using samples collected daily from women who were diagnosed with symptomatic BV (15 women), asymptomatic BV (6 women), and women who did not have BV (4 women). This unique resource of samples and data will contribute to a better understanding of the role that the vaginal microbes have in the natural history of BV and lead to improved diagnosis and treatment.
- 2 December 2013
- Published by Springer Nature in Microbiome
- Vol. 1 (1) , 29
Top Cited PapersOpen AccessDaily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis
Bacterial vaginosis (BV) is a common gynecologic diagnosis characterized by dysbiosis of the vaginal microbiota. It is often accompanied by vaginal symptoms such as odor and discharge, but can be asymptomatic. Despite over 50 years of research, the etiology of BV is not well understood, which is a major impediment to treatment and prevention of BV. Here we report on the temporal dynamics of 25 vaginal communities over a 10 week period using samples collected daily from women who were diagnosed with symptomatic BV (15 women), asymptomatic BV (6 women), and women who did not have BV (4 women). This unique resource of samples and data will contribute to a better understanding of the role that the vaginal microbes have in the natural history of BV and lead to improved diagnosis and treatment.
- 1 September 2013
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 40 (9) , 710-714
Intravaginal Metronidazole/Miconazole for the Treatment of Vaginal Trichomoniasis
Trichomonas vaginalis is the causative agent of the most common curable sexually transmitted disease in the world. The infection is treated with a single oral dose of metronidazole or tinidazole, currently the only licensed class of drugs available for this indication; however, both of these antimicrobials are associated with significant gastrointestinal adverse effects, and some individuals are unable to tolerate them because of these adverse effects. Randomized, dose-ranging pilot study conducted in 2 phases consisting of 20 participants in each phase. In the first phase, participants were randomized to the vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) twice a day for 7 days versus oral metronidazole 2 g single dose. In the second phase, participants randomized to suppository used it once a day for 7 days. Women were reevaluated on days 12 to 15 and 30 to 35. Treatment failures were defined as persistence of trichomonas by wet prep and/or culture. There were no significant differences in cure rates between the vaginal suppositories and oral metronidazole in either phase. The overall efficacy across both follow-up visits was 80% versus 90% for the suppository (2×/d) versus oral medication arms in phase 1 (P = 1.00) and 78% versus 70% for the suppository (1×/d) versus oral medication arms in phase 2 (P = 1.00). The results were also nonsignificant when combining results across arm (P = 1.00). High-dose intravaginal metronidazole combined with miconazole offers the possibility of a well-tolerated treatment that avoids the systemic adverse effects of nitroimidazoles for the treatment of trichomoniasis.
- 1 September 2013
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 40 (9) , 710-714
Intravaginal Metronidazole/Miconazole for the Treatment of Vaginal Trichomoniasis
Trichomonas vaginalis is the causative agent of the most common curable sexually transmitted disease in the world. The infection is treated with a single oral dose of metronidazole or tinidazole, currently the only licensed class of drugs available for this indication; however, both of these antimicrobials are associated with significant gastrointestinal adverse effects, and some individuals are unable to tolerate them because of these adverse effects. Randomized, dose-ranging pilot study conducted in 2 phases consisting of 20 participants in each phase. In the first phase, participants were randomized to the vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) twice a day for 7 days versus oral metronidazole 2 g single dose. In the second phase, participants randomized to suppository used it once a day for 7 days. Women were reevaluated on days 12 to 15 and 30 to 35. Treatment failures were defined as persistence of trichomonas by wet prep and/or culture. There were no significant differences in cure rates between the vaginal suppositories and oral metronidazole in either phase. The overall efficacy across both follow-up visits was 80% versus 90% for the suppository (2×/d) versus oral medication arms in phase 1 (P = 1.00) and 78% versus 70% for the suppository (1×/d) versus oral medication arms in phase 2 (P = 1.00). The results were also nonsignificant when combining results across arm (P = 1.00). High-dose intravaginal metronidazole combined with miconazole offers the possibility of a well-tolerated treatment that avoids the systemic adverse effects of nitroimidazoles for the treatment of trichomoniasis.